Sign in
Taking people in United StatesPhase 1/2

Testing a radioactive lead-212 drug in solid tumors with FAP protein

Tests a lead-212 radiation drug in adults with FAP-positive solid tumors.

Key facts

Who runs it
Perspective Therapeutics
Where
Cleveland, Columbus, Dallas, Houston, Kansas City, Lexington, Los Angeles, Madison, Miami, New York, Omaha, Pittsburgh, Rochester, and St Louis, United StatesSee the 16 sites
Trial code
Registry title
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
112 people, planned
Started
28 Apr 2025
Expected to end
28 May 2032
Type of study
Interventional, 2 groups
Treatments tested
  • [203Pb]Pb-PSV359
  • [212Pb]Pb-PSV359
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a solid tumour that has spread or grown locally and is growing despite standard treatment. A scan must show the study drug taken up in at least 1 known lesion.

Age
18 to 90 years
Sex
All sexes can join.
Disease stage
Locally advanced or metastatic solid tumour, confirmed by tissue or cell tests. The disease is progressing despite standard therapy, or no standard therapy exists.
Earlier treatment
No systemic anticancer therapy in the 4 weeks before treatment on the study. No major surgery within 21 days before the [212Pb]Pb-PSV359 dose.
Biomarker or test result
A positive [203Pb]Pb-PSV359 SPECT/CT scan showing uptake in at least 1 known lesion on the 1-hour scan.

Main reasons for not taking part

  • Pregnancy or breastfeeding a child
  • Known brain metastases
  • Active secondary malignancy
  • Known hypersensitivity or severe allergic reaction to the study drug or its excipients
  • Active or uncontrolled infection needing antifungals or antibiotics in the 3 days before enrollment

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Aged ≥ 18 years
  • Satisfactory organ function as determined by laboratory testing
  • Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1
  • Life expectancy > 3 months
  • Progressive disease despite standard therapy or for whom no standard therapy exists
  • Positive [203Pb]Pb-PSV359 SPECT/CT scan showing uptake of [203Pb]Pb-PSV359 in at least 1 known lesion on the 1-hour SPECT/ CT scan
  • Histological, pathological, and/or cytological confirmation of solid tumor malignancy that is locally advanced or metastatic

Who cannot take part

  • Known active or uncontrolled infections requiring ongoing antifungals or antibiotics in the 3 days prior to enrollment
  • Existence of any medical or social issues likely to interfere with study conductor that may cause increased risk to the subject or to others, e.g., lack of ability to follow radiation safety precautions
  • Medical history of a condition resulting in a severe allergic reaction such as anaphylaxis or angioedema to known components of the investigational product or excipients
  • Major surgery within 21 days prior to the administration of [212Pb]Pb-PSV359; the subject must be sufficiently recovered and stable before treatment administration
  • Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to enrollment into the study
  • Current abuse of alcohol or illicit drugs
  • Treatment with any live/attenuated vaccine in the 7 days prior to enrollment
  • Previous treatment with any systemic anticancer therapy within 4 weeks prior to treatment on study
  • Known hypersensitivity to the active agent or any of the excipients
  • Active secondary malignancy
  • Known medical condition which would make this protocol unreasonably hazardous for the patient
  • Pregnancy or breastfeeding a child
  • Known brain metastases

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

Where in United States

  • Cleveland ClinicCleveland, United StatesContact: Cancer Answer LineTaking people
  • Ohio State UniversityColumbus, United StatesContact: Pierce BurrisTaking people
  • UT Southwestern University Hospital Radiology ClinicDallas, United StatesContact: Radiology Clinical Research CenterTaking people
  • MD Anderson Cancer CenterHouston, United StatesContact: Brian BrionesTaking people
  • University of KansasKansas City, United StatesContact: KUCC Nurse NavigationTaking people
  • University of KentuckyLexington, United StatesContact: Sarah MartinTaking people
  • UCLA Department of Medicine - Hematology/OncologyLos Angeles, United StatesContact: Lim ChristopherTaking people
  • VA Greater Los Angeles Healthcare SystemLos Angeles, United StatesContact: Janake WijesuriyaTaking people
  • University of WisconsinMadison, United StatesContact: Cancer ConnectTaking people
  • BiogenixMiami, United StatesContact: Jerry JosephTaking people
  • University of MiamiMiami, United StatesContact: Sandel CeperoTaking people
  • Memorial Sloan Kettering Cancer Center - Main CampusNew York, United StatesContact: Daisy YascaribayTaking people
  • Nebraska Cancer SpecialistsOmaha, United StatesContact: Hanna KurzTaking people
  • University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Eunice AcampadoTaking people
  • Mayo Clinic in Rochester, MinnesotaRochester, United StatesContact: Cancer Center Clinical Trials Referral OfficeTaking people
  • Saint Louis UniversitySt Louis, United StatesContact: Anna ScannellTaking people

About the trial

What the trial wants to find out

Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

The 2 groups in the trial

  • Dose EscalationTreatment being tested

    * Enrolled subjects are administered \[203Pb\]Pb-PSV359 (7mCi) for imaging FAP-expressing cancers. * Approximately Four cohorts of \[212Pb\]Pb-PSV359 dose levels will be explored for determining Recommended Phase 2 Dose (RP2D). Study subjects will be assigned to cohorts sequentially.

    Treatment: [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359

  • Dose ExpansionTreatment being tested

    * Enrolled subjects are administered \[203Pb\]Pb-PSV359 (7mCi) for imaging FAP-expressing cancers. * Enrolled subjects are administered \[212Pb\]Pb-PSV359 (RP2D determined previously) for treatment of FAP-expressing cancers

    Treatment: [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive
Plain-language title
Testing a radioactive lead-212 drug in solid tumors with FAP proteinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06710756, who can take part
Publications
Record updated
28 October 2026